On the 13th, the National Medical Insurance Bureau issued an announcement to solicit public opinions on the "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog Adjustment Work Plan" and related documents.

  Compared with 2021, the Work Plan has remained generally stable, while improvements have been made in terms of application scope, access rules, and review procedures.

This year's medical insurance drug list, on the basis of continuing to support the new coronavirus pneumonia treatment drugs and innovative drugs, fully reflects the attention to rare disease treatment drugs and children's drugs, and includes "rare disease treatment drugs approved for marketing before June 30, 2022" "Drugs approved for marketing before June 30, 2022 and included in the list of children's drugs encouraged for R&D application" are clearly included in the application conditions, and the level of drug protection for relevant groups is expected to be further improved.

In addition, this year's catalog also proposed the rules for the access of non-exclusive drugs for the first time, increased the announcement of application results, and improved the expert review process. Overall, this year's medical insurance drug catalog adjustment is in the direction of science, standardization, fairness and transparency. Another solid step.

  It is reported that in the next step, the National Medical Insurance Administration will officially start the adjustment of the National Medical Insurance Drug List in 2022.

  (CCTV reporter Zhang Ping and Zheng Yizhe)